The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation

The class I phosphoinoside-3-kinases (PI3Ks) are important enzymes that relay signals from cell surface receptors to downstream mediators driving cellular functions. Elevated PI3K signaling is found in B cell malignancies and lymphocytes of patients with autoimmune disease. The p110δ catalytic isoform of PI3K is a rational target since it is critical for B lymphocyte development, survival, activation, and differentiation. In addition, activating mutations in PIK3CD encoding p110δ cause a human immunodeficiency known as activated PI3K delta syndrome. Currently, idelalisib is the only selective p110δ inhibitor that has been FDA approved to treat certain B cell malignancies. p110δ inhibitors can suppress autoantibody production in mouse models, but limited clinical trials in human autoimmunity have been performed with PI3K inhibitors to date. Thus, there is a need for additional tools to understand the effect of pharmacological inhibition of PI3K isoforms in lymphocytes. In this study, we tested the effects of a potent and selective p110δ inhibitor, IPI-3063, in assays of B cell function. We found that IPI-3063 potently reduced mouse B cell proliferation, survival, and plasmablast differentiation while increasing antibody class switching to IgG1, almost to the same degree as a pan-PI3K inhibitor. Similarly, IPI-3063 potently inhibited human B cell proliferation in vitro. The p110γ isoform has partially overlapping roles with p110δ in B cell development, but little is known about its role in B cell function. We found that the p110γ inhibitor AS-252424 had no significant impact on B cell responses. A novel dual p110δ/γ inhibitor, IPI-443, had comparable effects to p110δ inhibition alone. These findings show that p110δ is the dominant isoform mediating B cell responses and establish that IPI-3063 is a highly potent molecule useful for studying p110δ function in immune cells.

[1]  P. Hawkins,et al.  PI3K signalling in inflammation. , 2015, Biochimica et biophysica acta.

[2]  Xiaolin Hao,et al.  Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease. , 2015, Journal of medicinal chemistry.

[3]  D. Fruman,et al.  mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition , 2014, Proceedings of the National Academy of Sciences.

[4]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[5]  Bonnie Tillotson,et al.  PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. , 2013, Chemistry & biology.

[6]  Nada Jabado,et al.  Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage , 2013, Science.

[7]  J. B. Oliveira,et al.  Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency , 2013, Nature Immunology.

[8]  T. Rao,et al.  PI3Kγ kinase activity is required for optimal T-cell activation and differentiation , 2013, European journal of immunology.

[9]  Mengrou Lu,et al.  Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function* , 2012, The Journal of Biological Chemistry.

[10]  D. Whittington,et al.  Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors. , 2012, Journal of medicinal chemistry.

[11]  M. Gold,et al.  Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies , 2012, Front. Immun..

[12]  D. Fruman,et al.  Akt and mTOR in B Cell Activation and Differentiation , 2012, Front. Immun..

[13]  C. Rommel,et al.  PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic. , 2011, Cancer discovery.

[14]  E. Hirsch,et al.  Phosphoinositide 3‐kinase p110γ in immunity , 2011, IUBMB life.

[15]  J. Alferink,et al.  The catalytic PI3K isoforms p110γ and p110δ contribute to B cell development and maintenance, transformation, and proliferation , 2010, Journal of leukocyte biology.

[16]  Jason S. Mitchell,et al.  The p110γ isoform of phosphatidylinositol 3‐kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites , 2008, Journal of leukocyte biology.

[17]  S. Jameson,et al.  Selective Regulation of CD8 Effector T Cell Migration by the p110γ Isoform of Phosphatidylinositol 3-Kinase1 , 2008, The Journal of Immunology.

[18]  K. Calame,et al.  Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. , 2006, Immunity.

[19]  C. Rommel,et al.  Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. , 2006, Journal of medicinal chemistry.

[20]  K. Okkenhaug,et al.  Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. , 2006, Blood.

[21]  K. Okkenhaug,et al.  Cutting Edge: Differential Roles for Phosphoinositide 3-Kinases, p110γ and p110δ, in Lymphocyte Chemotaxis and Homing1 , 2004, The Journal of Immunology.

[22]  K. Okkenhaug,et al.  Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice , 2002, Science.

[23]  W L Stanford,et al.  Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. , 2000, Science.

[24]  F. Alt,et al.  Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. , 1999, Science.

[25]  M. Gold,et al.  Phosphoinositide 3-Kinase p110 Regulates Natural Antibody Production, Marginal Zone and B-1 B Cell Function, and Autoantibody Responses , 2009 .

[26]  K. Okkenhaug,et al.  Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. , 2004, Journal of immunology.